Metastatic melanoma cells Photo: Julio C. Valencia / NCI Center for Cancer Research

For the first time, scientists showed that personal vaccines targeting existing cancer tumors are feasible and safe in humans, via two separate, small clinical studies published Wednesday in Nature (here and here).

In fact, both studies reported that around 60% of their patients with advanced-stage melanoma were tumor-free for 12 to 32 months after receiving their personalized vaccine regimen. And, all of the patients showed some level of T-cell immune response — usually a strong level — after the vaccinations, meaning that, at the very least, the shots appear to jumpstart the immune system.

"Finally. The war against cancer really started 40 years ago but we have just started being smarter" on tackling it, Siwen Hu-Lieskovan, UCLA oncologist who was not part of these studies, told Axios. "Instead of trying to burn, poison or cut [the cancer] out, we've become smarter. We can utilize the patient's own immune system as a weapon against cancer."

Yes, but: These studies are both very small (one vaccinated 6 people, the other 13), which means it is "not overwhelming evidence," Hu-Lieskovan said. Other serious limitations include the overall cost and the long lag time between biopsying the tumor and sequencing the mutations to developing the vaccines (ranging from 3 to 5 months, although the process now is more automated, reducing the needed time).

Both studies:

  • Selected melanoma patients with high risk of recurrence, because this cancer is known to usually respond to immunotherapy (so if the scientists can't get a response from melanoma, they know it would very difficult to get it from other cancers).
  • Decided to target the neoantigen proteins on the cell surface that are produced by DNA mutations. Neoantigens are present in cancer cells but not in normal cells, making them an ideal tumor-specific target for immune therapy.
  • Showed negligible side effects from the vaccines.
  • Post vaccination results included: a lower-than-expected level of tumor recurrence, a significantly lower rate of metastasis, and showed that the addition of other immunotherapy treatments (like anti-PD-1) is usually very effective for those cases where there was tumor growth.

While the studies show many similarities, they used different steps to reach their conclusion.

U.S. vaccine study details: The scientists selected 10 people for their study, and determined 6 were eligible for the vaccine. The team operated and removed the patients' tumors, sequenced tumor and normal cells, selected up to 20 mutations/person, and made the peptides to put into the vaccine. The vaccines, which were started an average of 18 weeks after the surgery, were injected subcutaneously into four sites, five times over three weeks plus two booster shots later.

  • Out of the 6 who received the vaccine, 4 showed no evidence of cancer recurrence. The other 2 patients showed cancer had spread to the lungs, and they received an additional treatment of a PD-1 inhibitor, later showing a complete resolution of their tumors.

"We found strong immune response in all 6 patients that were vaccinated," Dana Farber's Patrick Ott, a study author, told Axios. "What the vaccine can do is to steer the immune response specifically to the cancer."

E.U. vaccine study details: This team selected 13 people, took samples of tumor and blood cells, sequenced everything, selected up to 10 different mutated neoantigens per person and engineered it into synthetic RNAs, which were injected into the lymph nodes for up to 20 doses per patient.

  • Out of the 13 who received the vaccine, 8 remained free of tumors and the remaining 5 had tumor relapses. Out of the remaining, two died, one had complete regression of tumors after being given a PD-1 inhibitor, and one had a mutation that did not allow the the vaccine to work.

Ugur Sahin, study author and CEO of BioNTech, said, "Although the study was not designed to see clinical efficacy, we found early evidence for the anti-tumoral activity of the vaccine."

Further study needed: "The two studies confirm the potential of this type of approach, and improvements in neoantigen prediction will probably allow the even more efficient and precise identification of neoantigens for use in therapeutic vaccines in the future. Although the numbers of people who were treated in these studies were small, both studies indicated potential benefits," cancer immunologist Cornelis Melief wrote in his Nature commentary on the studies.

Melief said controlled, randomized phase II clinical trials with more participants are needed to establish the efficacy of these vaccines in patients with any type of cancer that have neoantigen targets.

Go deeper

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 9 p.m. ET: 18,187,396 — Total deaths: 691,352 — Total recoveries — 10,841,436Map.
  2. U.S.: Total confirmed cases as of 9 p.m. ET: 4,711,323 — Total deaths: 155,379 — Total recoveries: 1,513,446 — Total tests: 57,543,852Map.
  3. Politics: White House will require staff to undergo randomized coronavirus testing — Pelosi says Birx "enabled" Trump on misinformation.
  4. Sports: 13 members of St. Louis Cardinals test positive, prompting MLB to cancel Tigers series — Former FDA chief says MLB outbreaks should be warning sign for schools.
  5. 1 🎥 thing: "Tenet" may be the first major film to get a global pandemic release.

In photos: Thousands evacuated as Southern California fire grows

A plane makes a retardant drop on a ridge at the Apple Fire north of Banning in Riverside County, which "doubled in size" Saturday, per KTLA. Robert Gauthier / Los Angeles Times via Getty Images

A massive wildfire that prompted mandatory evacuations in Southern California over the weekend burned 26,450 acres and was 5% contained by Monday afternoon, the California Department of Forestry and Fire Protection said.

The big picture: As California remains an epicenter of the coronavirus pandemic in the U.S., some 15 separate fires are raging across the state. About 7,800 people were under evacuation orders from the Apple Fire, about 75 miles east of Los Angeles, as hundreds of firefighters battled the blaze. CalFire said Monday that a malfunction involving a "diesel-fueled vehicle emitting burning carbon from the exhaust system" started the Apple Fire.

Twitter faces FTC fine of up to $250 million over alleged privacy violations

Photo: Rafael Henrique/SOPA Images/LightRocket

The Federal Trade Commission has accused Twitter of using phone numbers and emails from its users to make targeted ads between 2013 and 2019, Twitter said in an SEC filing published Monday.

Why it matters: Twitter estimates that the FTC's draft complaint, which was sent a few days after its Q2 earnings report, could cost the company between $150 million and $250 million. The complaint is unrelated to the recent Twitter hack involving a bitcoin scam.